Radiotherapy is a mainstay of efficient treatment of brain metastases from solid tumors. Immunotherapy has improved the survival of metastatic cancer patients across many tumor types. However, targeted therapy is a feasible alternative for patients unable to continue immunotherapy or with poor outcomes of immunotherapy. The combination of radiotherapy and targeted therapy for the treatment of brain metastases has a strong theoretical underpinning, but data on the efficacy and safety of this combination is still limited. A systematic search of PubMed, Embase, Web of Science and the Cochrane library database was conducted. Eleven studies were included for a total of 316 patients. Median OS was about 6.2-17.8 months from radiotherapy. Weighted survival and local control at 1 and 2 years were correlated (50.1 and 17.8%, 90.7 and 14.7% at 1 and 2 year, respectively). Radiotherapy given before or concurrently to targeted therapy provided the best effect on the outcome. For patients with brain metastases from cutaneous melanoma, the addition of concurrent targeted therapy to brain radiotherapy can increase survival and provide long-term control.

中文翻译：

---

放射治疗和靶向治疗相结合治疗黑色素瘤脑转移：系统评价。

放射治疗是有效治疗实体瘤脑转移的主要手段。免疫疗法改善了多种肿瘤类型的转移性癌症患者的生存率。然而，对于无法继续免疫治疗或免疫治疗效果不佳的患者来说，靶向治疗是一种可行的替代方案。放疗和靶向治疗相结合治疗脑转移瘤具有很强的理论基础，但有关这种组合的疗效和安全性的数据仍然有限。对 PubMed、Embase、Web of Science 和 Cochrane 图书馆数据库进行了系统检索。共纳入 11 项研究，涉及 316 名患者。放疗后的中位 OS 约为 6.2-17.8 个月。1 年和 2 年加权生存率与局部控制相关（1 年和 2 年分别为 50.1% 和 17.8%、90.7% 和 14.7%）。在靶向治疗之前或同时进行放射治疗对结果效果最好。对于皮肤黑色素瘤脑转移患者，在脑部放射治疗的基础上添加同步靶向治疗可以提高生存率并提供长期控制。